Lundbeck Q3 2019 Financial Results

Lu AG06466: First-In-Class drug with broad potential in CNS * * Lu AG06466 modulates the endocannabinoid system preferentially in areas where neuronal circuits are excessively activated Initial trials ongoing in Tourette's and neuropathic pain Phase lb trial in adult TS patients demonstrated significant effects across multiple endpoints of tic reduction 200,000 patients in U.S. with severe disease¹) 大 Exploratory phase Ila trial ongoing (NCT03625453) Initiated in October 2018 48 adult patients with Tourette's Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration Change from baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) Headline results due in 2020 I Lu AG06466: First-in-Class drug with broad potential in CNS Neuropsychiatric disorders Movement disorders Initial indication • • • OCD Agitation ADHD Parkinson's Tardive dyskinesia Huntington's Tourette's 31 1) NIH - National Institute of Neurological Disorders and Stroke Lundbeck

View entire presentation